Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab¢ certolizumab pegol: Results of a phase II randomized, placebo-controlled trial with a re-treatment extension

British Journal of Dermatology

Volumn 167, Issue 1, 2012, Pages 180-190

  Reich, Kristian ^a,b   Ortonne, J P ^c   Gottlieb, A B ^d   Terpstra, I J ^e   Coteur, G ^e   Tasset, C ^e   Mease, P ^f  

^a DERMATOLOGIKUM HAMBURG   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITÉ CÔTE D'AZUR   (France)

^d TUFTS MEDICAL CENTER   (United States)

^e UCB PHARMA   (Belgium)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERTOLIZUMAB PEGOL; PLACEBO;

ADULT; AGED; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BLOODY DIARRHEA; BREAST DISEASE; BRONCHITIS; CHILL; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CONTUSION; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROENTERITIS; HEMATOMA; HERPES SIMPLEX; HUMAN; INFLUENZA; INJECTION SITE IRRITATION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MILIARY TUBERCULOSIS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHYSICIAN GLOBAL ASSESSMENT; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RETREATMENT; RHINITIS; RHINOPHARYNGITIS; SORE THROAT; TENDINITIS; TONSILLITIS; URINARY TRACT INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PSORIASIS; RECURRENCE; RETREATMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863336589     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.10941.x     Document Type: Article

References (38)

1. Menter A, Gottlieb A, Feldman SR et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58:826-50. (Pubitemid 351509656)
2. National Institute for Health and Clinical Excellence. Ustekinumab for the Treatment of Adults with Moderate to Severe Psoriasis. London: NICE, 2009. Available at: http://guidance.nice.org.uk/TA180/Guidance/pdf/English (last accessed 23 April 2012).
3. Raval K, Lofland JH, Waters H et al. Disease and treatment burden of psoriasis: examining the impact of biologics. J Drugs Dermatol 2011; 10:189-96.
4. Nesbitt A, Fossati G, Bergin M et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007; 13:1323-32. (Pubitemid 350206841)
5. Bourne T, Fossati G, Nesbitt A. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action. BioDrugs 2008; 22:331-7.
6. Fleischmann R, Vencovsky J, van Vollenhoven RF et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009; 68:805-11.
7. Keystone E, Heijde DV, Mason D Jr et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-twoweek, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008; 58:3319-29.
8. Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357:228-38. (Pubitemid 47080387)
9. Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357:239-50. (Pubitemid 47080388)
10. Smolen J, Landewe RB, Mease P et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68:797-804.
11. Menter A, Tyring SK, Gordon K et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58:106-15. (Pubitemid 350298146)
12. Gordon KB, Langley RG, Leonardi C et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55:598-606. (Pubitemid 44436647)
13. Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51:534-42. (Pubitemid 39278071)
14. Griffiths CE, Strober BE, van de Kerkhof P et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362:118-28.
15. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349:2014-22. (Pubitemid 37448924)
16. Menter A, Feldman SR, Weinstein GD et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56:31.e1-15.
17. Papp KA, Tyring S, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152:1304-12. (Pubitemid 40933433)
18. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366:1367-74. (Pubitemid 41443403)
19. Saurat JH, Stingl G, Dubertret L et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158:558-66. (Pubitemid 351239154)
20. Sterry W, Ortonne JP, Kirkham B et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010; 340:c147.
21. van de Kerkhof PC, Segaert S, Lahfa M et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 2008; 159:1177-85.
22. Chaudhari U, Romano P, Mulcahy LD et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357:1842-7. (Pubitemid 32539117)
23. Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371:1665-74. (Pubitemid 351671883)
24. Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371:1675-84. (Pubitemid 351671884)
25. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005; 64 (Suppl. 2):ii65-8. (Pubitemid 40288526)
26. Bronsard V, Paul C, Prey S et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2):17-22.
27. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210-16. (Pubitemid 24194579)
28. Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists'guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161:987-1019.
29. Mrowietz U, Kragballe K, Reich K et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303:1-10.
30. Gniadecki R, Kragballe K, Dam TN et al. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011; 164:1091-6.
31. van Voorhees AS, Fried R. Depression and quality of life in psoriasis. Postgrad Med 2009; 121:154-61.
32. Feldman SR, Gottlieb AB, Bala M et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol 2008; 159:704-10.
33. Papp KA, Signorovitch J, Ramakrishnan K et al. Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials. Clin Drug Investig 2011; 31:51-60.
34. Reich K, Griffiths CE. The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. Arch Dermatol Res 2008; 300:537-44.
35. Feagan BG, Coteur G, Tan S et al. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease. Am J Gastroenterol 2009; 104:1976-83.
36. Han C, Smolen JS, Kavanaugh A et al. The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. Arthritis Res Ther 2007; 9:R103.
37. Strand V, Mease P, Burmester GR et al. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Res Ther 2009; 11:R170.
38. Hongbo Y, Thomas CL, Harrison MA et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 2005; 125:659-64.